Therma Bright Secures Major Purchase Order for Venowave Units, Boosting U.S. Market Penetration
Generado por agente de IAMarcus Lee
lunes, 13 de enero de 2025, 6:15 am ET1 min de lectura
THRM--
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a leading developer and investment partner in advanced diagnostic and medical device technologies, has secured a significant purchase order for its Venowave VW5 units from Valor Medical Solutions, a prominent national distribution partner based in San Antonio, Texas. This strategic partnership is set to enhance Therma Bright's market penetration in the U.S. healthcare sector and drive revenue growth.

The initial purchase order, valued at a minimum of $81,955 USD (approximately $117,952 CAD), covers 100 Venowave VW5 units. This order is a result of successful pilot tests around the HCPCS code reimbursement program, demonstrating Valor Medical's confidence in the device and its potential market demand. The distributor and its partners receive upwards of 100 doctor referrals per day for vascular compression therapy solutions, indicating a strong need for Therma Bright's innovative technology.
Valor Medical Solutions, a fast-growing distributorship of orthopedic implants and ancillary products, is committed to filling the immediate needs of its network of medical practitioners and their patients. The company anticipates increasing its purchase order amounts every few weeks as it builds greater awareness of the Venowave VW5 solution and the HCPCS code reimbursement program within its end client network. This strategic partnership is expected to generate steady revenue growth for Therma Bright throughout 2025 and beyond.

Rob Fia, CEO of Therma Bright, expressed his enthusiasm about the partnership, stating, "It's been an exciting journey for Therma Bright and its Venowave VW5 solution. We're thrilled to partner with Valor Medical, a company that has been very successful in growing its business. Our team looks forward to being part of Cindy's further growth, along with our other national distributors, helping them market, sell, and distribute our device within their medical communities. We anticipate great success of Venowave VW5 sales during 2025 and will provide market updates on our progress as required."
In conclusion, Therma Bright's strategic partnership with Valor Medical Solutions is poised to significantly enhance the company's market penetration in the U.S. healthcare sector. With a strong focus on driving revenue growth and expanding market reach, Therma Bright is well-positioned to capitalize on the growing demand for innovative medical devices and technologies.
TSVT--
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a leading developer and investment partner in advanced diagnostic and medical device technologies, has secured a significant purchase order for its Venowave VW5 units from Valor Medical Solutions, a prominent national distribution partner based in San Antonio, Texas. This strategic partnership is set to enhance Therma Bright's market penetration in the U.S. healthcare sector and drive revenue growth.

The initial purchase order, valued at a minimum of $81,955 USD (approximately $117,952 CAD), covers 100 Venowave VW5 units. This order is a result of successful pilot tests around the HCPCS code reimbursement program, demonstrating Valor Medical's confidence in the device and its potential market demand. The distributor and its partners receive upwards of 100 doctor referrals per day for vascular compression therapy solutions, indicating a strong need for Therma Bright's innovative technology.
Valor Medical Solutions, a fast-growing distributorship of orthopedic implants and ancillary products, is committed to filling the immediate needs of its network of medical practitioners and their patients. The company anticipates increasing its purchase order amounts every few weeks as it builds greater awareness of the Venowave VW5 solution and the HCPCS code reimbursement program within its end client network. This strategic partnership is expected to generate steady revenue growth for Therma Bright throughout 2025 and beyond.

Rob Fia, CEO of Therma Bright, expressed his enthusiasm about the partnership, stating, "It's been an exciting journey for Therma Bright and its Venowave VW5 solution. We're thrilled to partner with Valor Medical, a company that has been very successful in growing its business. Our team looks forward to being part of Cindy's further growth, along with our other national distributors, helping them market, sell, and distribute our device within their medical communities. We anticipate great success of Venowave VW5 sales during 2025 and will provide market updates on our progress as required."
In conclusion, Therma Bright's strategic partnership with Valor Medical Solutions is poised to significantly enhance the company's market penetration in the U.S. healthcare sector. With a strong focus on driving revenue growth and expanding market reach, Therma Bright is well-positioned to capitalize on the growing demand for innovative medical devices and technologies.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios